Fact CheckerSign in

NCT07716826Not yet recruiting

IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

Source: ClinicalTrials.gov · Last updated 21 Jul 2026

Brief summary (registry, in English)

The objective of this observational study is to evaluate the association between the presence of mitral valvular and/or subvalvular anatomical abnormalities prior to initiation of mavacamten and the hemodynamic response at 6 months in patients with obstructive HCM treated with mavacamten. The secondary objective is to determine the impact of different types of anatomical abnormalities of the mitral valve and subvalvular structures on the hemodynamic and clinical response to mavacamten.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
150 (estimated)
First submitted
16 Jul 2026
Start date
Sept 2026
Primary completion date
Dec 2026
Lead sponsor
French Cardiology Society
NCT number
NCT07716826

What you commit to

  • Study type: Observational
  • Planned participants: 150
  • From Sept 2026 to the primary completion date, Dec 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients who refuse to participate in this register

Who the study is looking for

  • Inclusion Criteria :
  • Age ≥18 years
  • Patients who are informed and consent to participate
  • CMH with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3)
  • Patients who have started treatment with Mavacamten

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.